274 related articles for article (PubMed ID: 30115664)
1. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Quanz M; Bender E; Kopitz C; Grünewald S; Schlicker A; Schwede W; Eheim A; Toschi L; Neuhaus R; Richter C; Toedling J; Merz C; Lesche R; Kamburov A; Siebeneicher H; Bauser M; Hägebarth A
Mol Cancer Ther; 2018 Nov; 17(11):2285-2296. PubMed ID: 30115664
[TBL] [Abstract][Full Text] [Related]
2. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R; Hodgkinson CL; Fusi A; Nonaka D; Priest L; Kelly P; Trapani F; Bishop PW; White A; Critchlow SE; Smith PD; Blackhall F; Dive C; Morrow CJ
Clin Cancer Res; 2014 Feb; 20(4):926-937. PubMed ID: 24277449
[TBL] [Abstract][Full Text] [Related]
3. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
4. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
Guan X; Rodriguez-Cruz V; Morris ME
AAPS J; 2019 Jan; 21(2):13. PubMed ID: 30617815
[TBL] [Abstract][Full Text] [Related]
5. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Puri S; Juvale K
Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
Noble RA; Bell N; Blair H; Sikka A; Thomas H; Phillips N; Nakjang S; Miwa S; Crossland R; Rand V; Televantou D; Long A; Keun HC; Bacon CM; Bomken S; Critchlow SE; Wedge SR
Haematologica; 2017 Jul; 102(7):1247-1257. PubMed ID: 28385782
[TBL] [Abstract][Full Text] [Related]
7. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
Beloueche-Babari M; Wantuch S; Casals Galobart T; Koniordou M; Parkes HG; Arunan V; Chung YL; Eykyn TR; Smith PD; Leach MO
Cancer Res; 2017 Nov; 77(21):5913-5924. PubMed ID: 28923861
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
9. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.
Le Floch R; Chiche J; Marchiq I; Naiken T; Ilc K; Murray CM; Critchlow SE; Roux D; Simon MP; Pouysségur J
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16663-8. PubMed ID: 21930917
[TBL] [Abstract][Full Text] [Related]
10. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.
Guan X; Bryniarski MA; Morris ME
AAPS J; 2018 Nov; 21(1):3. PubMed ID: 30397860
[TBL] [Abstract][Full Text] [Related]
12. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments.
Contreras-Baeza Y; Sandoval PY; Alarcón R; Galaz A; Cortés-Molina F; Alegría K; Baeza-Lehnert F; Arce-Molina R; Guequén A; Flores CA; San Martín A; Barros LF
J Biol Chem; 2019 Dec; 294(52):20135-20147. PubMed ID: 31719150
[TBL] [Abstract][Full Text] [Related]
13. A Nonradioactive High-Throughput Screening-Compatible Cell-Based Assay to Identify Inhibitors of the Monocarboxylate Transporter Protein 1.
Bailey TL; Nieto A; McDonald PH
Assay Drug Dev Technol; 2019 Aug; 17(6):275-284. PubMed ID: 31532712
[No Abstract] [Full Text] [Related]
14. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.
Walters DK; Arendt BK; Jelinek DF
Cell Cycle; 2013 Oct; 12(19):3175-83. PubMed ID: 24013424
[TBL] [Abstract][Full Text] [Related]
15. Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition.
Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT
Oncogene; 2020 Apr; 39(17):3555-3570. PubMed ID: 32123312
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.
Guan X; Morris ME
AAPS J; 2020 Jun; 22(4):84. PubMed ID: 32529599
[TBL] [Abstract][Full Text] [Related]
17. Monocarboxylate transporters 1 and 4: expression and regulation by PPARα in ovine ruminal epithelial cells.
Benesch F; Dengler F; Masur F; Pfannkuche H; Gäbel G
Am J Physiol Regul Integr Comp Physiol; 2014 Dec; 307(12):R1428-37. PubMed ID: 25320343
[TBL] [Abstract][Full Text] [Related]
18. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Benjamin D; Robay D; Hindupur SK; Pohlmann J; Colombi M; El-Shemerly MY; Maira SM; Moroni C; Lane HA; Hall MN
Cell Rep; 2018 Dec; 25(11):3047-3058.e4. PubMed ID: 30540938
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
20. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity.
Nancolas B; Sessions RB; Halestrap AP
Biochem J; 2015 Feb; 466(1):177-88. PubMed ID: 25437897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
